Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

William HK Schilling; James J. Callery; Walter Taylor; Mavuto Mukaka; Maneerat Ekkapongpisit; James A Watson; Arjun Chandna; Salwaluk Panapipat; Jaruwan Tubprasert; Prayoon Yuentrakul; Naomi Waithira; Tanya Cope; Mehul Dhorda; Cintia Cruz; Lorenz von Seidlein; Joanne Milton; Martin Llewelyn; Amanda Adler; Kesinee Chotivanich; Phaik Yeong Cheah; Elizabeth A. Ashley; Mayfong Mayxay; Arjen M. Dondorp; Weerapong Phumratanaprapin; Nicholas Day; Sir Nicholas White

doi:10.12688/wellcomeopenres.15784.1

Verified authors • Institutional access • DOI aware

50,000+ researchers120,000+ datasets90% satisfaction

Preprint

English

2020

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

0 Datasets

0 Files

English

2020

Wellcome Open Research

Vol 5

DOI: 10.12688/wellcomeopenres.15784.1

Get instant academic access to this publication’s datasets.

Create free account How it works

Frequently asked questions

Is access really free for academics and students?

Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.

How is my data protected?

Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.

Can I request additional materials?

Yes, message the author after sign-up to request supplementary files or replication code.

Advance your research today

Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.

Get free academic access Learn more

✓ Immediate verification • ✓ Free institutional access • ✓ Global collaboration

There is no proven preventative therapy or vaccine against COVID-19. Theinfection has spread rapidly and there has already been a substantial adverse impact on the global economy. Healthcare workers have been affected disproportionately in the continuing pandemic. Significant infection rates in this critical group have resulted in a breakdown of health services in some countries. Chloroquine, and the closely related hydroxychloroquine, are safe and well tolerated medications which can be given for years without adverse effects. Chloroquine and hydroxychloroquine have significant antiviral activity against SARS-CoV-2, and despite the lack of benefit of hydroxychloroquine treatment in patients hospitalised with severe COVID-19, these drugs could still work in prevention. The emerging infection paradigm of an early viral peak, and late inflammation where there is benefit from corticosteroids. If these direct actiing antivirals are to work, they have the best chance given either early in infection and before infection occurs. We describe the study protocol for a multi-centre, multi-country randomised, double blind, placebo controlled trial to answer the question- can chloroquine/ hydroxychloroquine prevent COVID-19. 40,000 participants working in healthcare facilities or involved in the management of COVID-19 will be randomised 1:1 to receive chloroquine/ hydroxychloroquine or matched placebo as daily prophylaxis for three months. The primary objective is the prevention of symptomatic, virological or serologically proven coronavirus disease (COVID-19). The study could detect a 23% reduction from an incidence of 3% in the placebo group for either drug with 80% power. Secondary objectives are to determine if chloroquine/hydroxychloroquine prophylaxis attenuates severity, prevents asymptomaticCOVID-19 and symptomatic acute respiratory infections of another aetiology (non-SARS-CoV-2).

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

Frequently asked questions

Is access really free for academics and students?

How is my data protected?

Can I request additional materials?

Advance your research today

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

Frequently asked questions

Is access really free for academics and students?

How is my data protected?

Can I request additional materials?

Advance your research today

Access Research Data

This PDF is not available in different languages.

Sir Nicholas White

Abstract

How to cite this publication

Related publications

Why join Raw Data Library?

Quality

Control

Free for Academia

Publication Details

Join Research Community